Transatlantique Private Wealth LLC Buys New Shares in iShares Biotechnology ETF (NASDAQ:IBB)

Transatlantique Private Wealth LLC purchased a new position in iShares Biotechnology ETF (NASDAQ:IBB) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,680 shares of the financial services provider’s stock, valued at approximately $231,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of IBB. Future Financial Wealth Managment LLC purchased a new position in shares of iShares Biotechnology ETF during the 1st quarter valued at $27,000. Bbjs Financial Advisors LLC bought a new stake in iShares Biotechnology ETF during the second quarter valued at about $31,000. Pacifica Partners Inc. lifted its position in shares of iShares Biotechnology ETF by 118.2% in the first quarter. Pacifica Partners Inc. now owns 240 shares of the financial services provider’s stock valued at $33,000 after acquiring an additional 130 shares in the last quarter. YHB Investment Advisors Inc. bought a new position in shares of iShares Biotechnology ETF in the first quarter worth about $37,000. Finally, Mather Group LLC. bought a new position in shares of iShares Biotechnology ETF in the first quarter worth about $57,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

NASDAQ IBB opened at $147.98 on Friday. iShares Biotechnology ETF has a 12 month low of $111.83 and a 12 month high of $150.57. The stock’s 50 day moving average is $145.80 and its 200 day moving average is $138.62.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.